Supernus Pharmaceuticals Files 8-K Report

Ticker: SUPN · Form: 8-K · Filed: 2024-08-01T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

SUPERNUS PHARMACEUTICALS FILES ROUTINE 8-K. NO MAJOR NEWS.

AI Summary

On August 1, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of an event and does not contain specific financial figures or significant business updates beyond its routine nature. The company, incorporated in Delaware, maintains its principal executive offices in Rockville, MD.

Why It Matters

This 8-K filing indicates a routine update or event notification from Supernus Pharmaceuticals, Inc. to the SEC, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report, indicating no immediate or significant new risks are being disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Supernus Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report an event or series of events that have occurred or are expected to occur, as required by Section 13 or 15(d) of the Securities Exchange Act of 1934.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing occurred on August 1, 2024.

In which state is Supernus Pharmaceuticals, Inc. incorporated?

Supernus Pharmaceuticals, Inc. is incorporated in Delaware.

What is the address of Supernus Pharmaceuticals, Inc.'s principal executive offices?

The address of Supernus Pharmaceuticals, Inc.'s principal executive offices is 9715 Key West Ave, Rockville, MD 20850.

Does this 8-K filing disclose any specific financial results or material business changes?

Based on the provided text, this 8-K filing is a current report pursuant to Section 13 or 15(d) and does not appear to disclose specific financial results or material business changes beyond the notification of an event.

Filing Stats: 684 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-08-01 16:58:35

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events On August 1, 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release announcing that it had resubmitted its New Drug Application (NDA) for SPN-830 (apomorphine infusion device) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. This Current Report on Form 8-K contains "forward-looking statements" that do not convey historical information, but relate to predicted or potential future events, such as statements of our plans, strategies and intentions. These statements can often be identified by the use of forward-looking terminology such as "believe," "expect," "intend," "may," "will," "should," or "anticipate" or similar terminology. All statements other than statements of historical facts included in this Current Report on Form 8-K are forward-looking statements. All forward-looking statements speak only as of the date of this Current Report on Form 8-K. Except for Supernus' ongoing obligations to disclose material information under the federal securities laws, Supernus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In addition to the risks and uncertainties of ordinary business operations and conditions in the general economy and the markets in which Supernus competes, the forward-looking statements of Supernus contained in this Current Report on Form 8-K are also subject to various risks and uncertainties, including those set forth in Item 1A, "Risk Factors," in Supernus' Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 — Press Release Dated August 1, 2024 furnished as an Exhibit pursuant to Item 8.01 hereof. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: August 1, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3

View on Read The Filing